Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In a statement to Insider, Novo Nordisk, the company that makes Wegovy and Ozempic, said that Gila monsters and the discovery of exendin-4 "did not have anything to do with our decision to develop long-acting GLP-1 receptor agonists" for obesity, because "that was based on GLP-1 biology in humans." But the company also said that "the GLP-1-like effect of exendin-4" in Gila monsters was "an important contribution to the field," as it led to the development of the very first injectable drug of its kind
.jpg)
GLP-1R Lowers blood glucose by binding to GLP-1, mainly by stimulating insulin secretion and inhibiting glucagon secretion (Drucker, 2018)
Non-Hormonal : No PCT needed, safe for continuous use
GLP-1 Market Overview 2026 | Size, Share & Industry Trend 2034 REPORT DETAILS GLP-1 Market Summary The global GLP-1 market size was valued at USD 52.82 billion in 2025, growing at a CAGR of 10.9% during 20262034
Product Information and Quality NO GUARANTEES: While we strive for accuracy, we make no representations or warranties regarding the accuracy, completeness, reliability, or currency of any product information, specifications, or descriptions on our website
